Skip to main content
SpringerLink
Log in

Intraokulare Bevacizumab-Injektionen bei seltenen Indikationen – zwei Kasuistiken

Intraocular injections of bevacizumab in rare indications – two cases

  • Kasuistiken
  • Published:
Der Ophthalmologe Aims and scope Submit manuscript

Zusammenfassung

Intravitreale Anti-VEGF-Injektionen stellen derzeit die effektivste Therapiemöglichkeit der Behandlung der neovaskulären altersbedingten Makuladegeneration dar. Die Anti-VEGF-Behandlung anderer, häufiger okulärer Erkrankungen, wie z. B. diabetische Retinopathie und Zustand nach Gefäßverschlüssen, welche mit Neovaskularisationen und Netzhautödemen einhergehen, werden derzeit in zahlreichen Studien und Fallbeschreibungen untersucht. Ebenso sind seltenere neovaskuläre okuläre Erkrankungen, wie der Morbus Eales, das Presumed-Ocular-Histoplasmosis-Syndrom (POHS), die Retinopathia praematurorum, idiopathische Teleangieektasien etc. wahrscheinlich künftige Anwendungsgebiete für eine Anti-VEGF-Therapie. In unseren Kasuistiken berichten wir zum einen vom Therapieverlauf nach intravitrealer Bevacizumab- (Avastin®-)Injektion bei therapieresistenter Retinopathia centralis serosa sowie im zweiten Fall bei Pseudoxanthoma elasticum mit „angioid streaks“ und subretinaler Neovaskularisationsmembran (CNV).

In beiden Fällen konnte nach intravitrealer Injektion eine nahezu morphologische wie funktionelle Rehabilitation erreicht werden.

Abstract

Intravitreal anti-VEGF injections are currently the most effective treatment option for neovascular age-related macular degeneration. The anti-VEGF treatment of other, more common ocular diseases, such as diabetic retinopathy and vascular occlusions with neovascularization and retinal edema, is currently described in numerous studies and cases. Rare neovascular ocular diseases, such as Eales disease, presumed ocular histoplasmosis syndrome (POHS), retinopathy of prematurity, and idiopathic telangiectasia, may be future areas for anti-VEGF therapy. In our case report we describe intravitreal bevacizumab (Avastin®) therapy for central serous chorioretinopathy and for pseudoxanthoma elasticum with angioid streaks and choroidal neovascularization. In both cases the intravitreal injection resulted in morphological and functional rehabilitation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5
Abb. 6
Abb. 7
Abb. 8
Abb. 9
Abb. 10
Abb. 11
Abb. 12

Literatur

  1. Alfredo A et al. (2007) Intravitreal bevacizumab as initial treatment for choroidal neovascularization associated with presumed ocular histoplasmosis syndrome. Graefes Arch Clin Exp Ophthalmol 245: 1873–1875

    Article  CAS  Google Scholar 

  2. Avery RL, Pearlman J, Pieramici DJ et al. (2006) Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113: 1695–1705

    Article  PubMed  Google Scholar 

  3. Avery RL, Pieramici DJ, Rabena MD et al. (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113: 363–372

    Article  PubMed  Google Scholar 

  4. Bartz-Schmidt KU, Holz FG (2006) Bevacizumab-Therapie im „off label use“bei der neovaskulären altersabhängigen Makuladegeneration. Ophthalmologe 103: 461–462

    Article  PubMed  CAS  Google Scholar 

  5. Browning AC, Chung AK, Ghanchi F et al. (2005) Verteporfin photodynamic therapy of choroidal neovascularization in angioid streaks: one-year results of a prospective case series. Ophthalmology 112: 1227–1231

    Article  PubMed  Google Scholar 

  6. Chassaing N, Martin L, Calvas P et al. (2005) Pseudoxanthoma elasticum: a clinical, pa thophysiological and genetic upda te including 11 no vel ABCC6 mutations. J Med Genet 42: 881–892

    Article  PubMed  CAS  Google Scholar 

  7. Connor PJ jr, Juergens JL, Perry HO et al. (1961) Pseudoxanthoma elasticum and angioid streaks. A review of 106 cases. Am J Med 30: 537–543

    Article  PubMed  Google Scholar 

  8. Dreyer R, Green WR (1978) The pathology of angioid streaks: a study of twenty-one cases. Trans Pa Acad Ophthalmol Otolaryngol 31: 158–167

    PubMed  CAS  Google Scholar 

  9. Eun Jee Chung et al. (2007) Combination of laser photocoagulation and intravitreal bevacizumab (Avastin®) for aggressive zone I retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 245:1727–1730

    Article  CAS  Google Scholar 

  10. Geitzenauer W, Michels S, Prager F et al. (2006) Frühe Effekte nach systemischer und intravitrealer Bevacizumab (Avastin®)-Therapie bei neovaskulärer altersbedingter Makuladegeneration. Klin Monatsbl Augenheilkd 223: 822–827

    Article  PubMed  CAS  Google Scholar 

  11. Giovannini A, Scassellati-Sforzolini BD, Altobrando E (1997) Chorioidal findings in the course of idiopathic serous pigment epithelium detachment detected by indocyanine green videoangiography. Retina 17: 286–293

    PubMed  CAS  Google Scholar 

  12. Groenblad E (1958) Color photographs of angioid streaks in the late stages. Acta Ophthalmol (Copenh) 36: 472–474

    Google Scholar 

  13. Hacker SM, Ramos-Caro FA, Beers BB, Flowers FP (1993) Juvenile pseudoxanthoma elasticum: recognition and management. Pediatr Dermatol 10: 19–25

    Article  PubMed  CAS  Google Scholar 

  14. Heier JS, Antoszyk AN, Pavan PR et al. (2006) Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology 113(4): 642.e1–4. Epub 2006 Feb 14

    Article  Google Scholar 

  15. Hu X, Plomp AS, Van Soest S et al. (2003) Pseudoxanthoma elasticum: a clinical, histopathological, and molecular update. Surv Ophthalmol 48: 424–438

    Article  PubMed  Google Scholar 

  16. Hussain D, Gass JDM (1998) Idiopathic central serous chorioretinopathy. Indian J Ophthalmol. 3 131–137

    Google Scholar 

  17. Iturralde D, Spaide RF, Meyerle CB et al. (2006) Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion. A short-term study. Retina 26: 279–284

    Article  PubMed  Google Scholar 

  18. Jaissle GB, Ziemssen F, Petermeier K et al. (2006) Bevacizumab zur Therapie des sekundären Makulaödems nach venösen Gefäßverschlüssen. Ophthalmologe 103: 471–475

    Article  PubMed  CAS  Google Scholar 

  19. Jorge R et al. (2007) Intravitreal bevacizumab (Avastin) associated with the regression of subretinal neovascularization in idiopathic juxtafoveolar retinal telangiectasis. Graefes Arch Clin Exp Ophthalmol 245: 1045–1048

    Article  PubMed  CAS  Google Scholar 

  20. Kaiser P, ANCHOR Study Group (2006) ANCHOR DATA (year one results). Macula 2006, paper presentation, New York NY USA

  21. Knapp H (1892) On the formation of dark angioid streaks as an unusual metamorphosis of retinal hemorrage. Arch Ophthalmol 21: 289–292

    Google Scholar 

  22. Krill AE, Klien BA, Archer DB (1973) Precursors of angioid streaks. Am J Ophthalmol 76: 875–879

    PubMed  CAS  Google Scholar 

  23. Kumar A, Sinha S (2007) Rapid regression of disc and retinal neovascularization in a case of Eales disease after intravitreal bevacizumab. Can J Ophthalmol 42(2): 335

    Article  PubMed  Google Scholar 

  24. Ladewig MS, Ziemssen F, Jaissle G et al. (2006) Intravitreales Bevacizumab bei der neovaskulären altersabhängigen Makuladegeneration. Ophthalmologe 103: 463–70

    Article  PubMed  CAS  Google Scholar 

  25. Lebwohl M, Halperin J, Phelps RG (1993) Brief report: occult pseudoxanthoma elasticum in patients with premature cardiovascular disease. N Engl J Med 329: 1237–1239

    Article  PubMed  CAS  Google Scholar 

  26. Lim JI, Bressler NM, Marsh MJ, Bressler SB (1993) Laser treatment of choroidal neovascularization in patients with angioid streaks. Am J Ophthalmol 116: 414–423

    PubMed  CAS  Google Scholar 

  27. Lipowsky ZJ, Kiriakos RZ (1971) Psychosomatic aspects of central serous chorioretinopathy. Psychosom Med 12: 148–161

    Google Scholar 

  28. Lommatzsch et al. (2007) Intraokulare Injektion von Bevacizumab Eine mögliche Therapie der sekundären CNV bei „angioid streaks“. Ophthalmologe 104: 325–328

    Article  PubMed  CAS  Google Scholar 

  29. Ladewig MS (2006) Pseudoxanthoma elasticum Genetische Grundlagen, Manifestationen und therapeutische Ansätze. Ophthalmologe 103: 537–553

    Article  PubMed  CAS  Google Scholar 

  30. Olk JR, Burgess DB, McCormick PA (1984) Subfoveal and juxtafoveal subretinal neovascularization in the presumed ocular histoplasmosis syndrome (POHS): visual prognosis. Ophthalmology 91: 1592–1602

    PubMed  CAS  Google Scholar 

  31. Otsuka S, Ohba N, Nakao K (2002) A Long-Term Follow-Up Study of Severe Variant Of Central Serous Chorioretinopathy. Retina 22: 25–32

    Article  PubMed  Google Scholar 

  32. Pasquali-Ronchetti I, Volpin D, Baccarani-Contri M et al. (1981) Pseudoxanthoma elasticum. Biochemical and ultrastructural studies. Dermatologica 163: 307–325

    Article  PubMed  CAS  Google Scholar 

  33. Pece A, Avanza P, Galli L, Brancato R (1997) Laser photocoagulation of choroidal neovascularization in angioid streaks. Retina 17: 12–16

    PubMed  CAS  Google Scholar 

  34. Pierro L, Brancato R, Minicucci M, Pece A (1994) Echographic diagnosis of Drusen of the optic nerve head in patients with angioid streaks. Ophthalmologica 208: 239–242

    PubMed  CAS  Google Scholar 

  35. Pope FM (1975) Historical evidence for the genetic heterogeneity of pseudoxanthoma elasticum. Br J Dermatol 92: 493–509

    Article  PubMed  CAS  Google Scholar 

  36. Prünte C, Flammer J (1996) Chorioidal capillary and venous congestion in central serous chorioretinopathy. Am J Ophthalmol 121 26–34

    Google Scholar 

  37. Rosenfeld PJ, Rich RM, Lalwani GA (2006) Ranibizumab: Phase III clinical trial results. Ophthalmol Clin North Am 19(3): 361–72

    PubMed  Google Scholar 

  38. Roth DB, Estafanous M, Lewis H (2001) Macular translocation for subfoveal choroidal neovascularization in angioid streaks. Am J Ophthalmol 131: 390–392

    Article  PubMed  CAS  Google Scholar 

  39. Schneider T, Apel HP, Kuhlwein A et al. (1984) Groenblad-Strandberg Syndrom. Z Hautkrankh 59: 1290–1292, 1297–1300

    CAS  Google Scholar 

  40. Secretan M, Zografos L, Guggisberg D, Piguet B (1998) Chorioretinal vascular abnormalities associated with angioid streaks and pseudoxanthoma elasticum. Arch Ophthalmol 116: 1333–1336

    PubMed  CAS  Google Scholar 

  41. Shields JA, Federman JL, Tomer TL, Annesley WH jr (1975) Angioid streaks. I. Ophthalmoscopic variations and diagnostic problems. Br J Ophthalmol 59: 257–266

    Article  PubMed  CAS  Google Scholar 

  42. Sibayan SAB, Kobuch K, Spiegel D et al. (2000) Epinephrine, but not dexamethasone, induces apoptosis in retinal pigment epithelium cells in vitro: possible implications on the pathogenesis of central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 238: 515–519

    Article  PubMed  CAS  Google Scholar 

  43. Spaide RF, Laud K, Fine HF et al. (2006) Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26: 383–390

    Article  PubMed  Google Scholar 

  44. Spaide RF, Sorenson J, Maranan L (2003) Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 110: 1517–1525

    Article  PubMed  Google Scholar 

  45. Stark WJ jr, Maumenee AE, Fagadau W et al. (1984) Cystoid macular edema in pseudophakia. Surv Ophthalmol 28: 442–451

    Article  PubMed  Google Scholar 

  46. Thoelen AM, Bernasconi PP, Schmid C, Messmer E (2000) Central serous chorioretinopathy associated with a carcinoma of the adrenal cortex. Retina 20: 98–99

    PubMed  CAS  Google Scholar 

  47. Tittl MK, Spaide RF, Wong D (1999) Systemic findings associated with central serous chorioretinopathy. Am J Ophthalmol 128: 63–68

    Article  PubMed  CAS  Google Scholar 

  48. Völcker S, Peters W, Inhoffen F, Ziemssen (2006) Früher antiexsudativer Effekt – OCT-Monitoring nach intravitrealer Bevacizumab-Applikation. Ophthalmologe 103: 476–483

    Article  PubMed  CAS  Google Scholar 

  49. Weis SM, Cheresh DA (2005) Pathophysiological consequences of VEGF-induced vascular permeability. Nature 437: 497–504

    Article  PubMed  CAS  Google Scholar 

  50. Whittles CE, Pocock TM, Wedge SR et al. (2002) ZM323881, a novel inhibitor of vascular endothelial growth factor-receptor-2 tyrosine kinase activity. Microcirculation 9: 513–522

    Article  PubMed  CAS  Google Scholar 

  51. Yannuzzi L.A (1987) Type A behavior and central serous chorioretinopathy. Retina 7 111–130

    Google Scholar 

  52. Yoshioka H, Katsume Y, Akune H (1982) Experimental central serous chorioretinopathy in monkey eyes: Fluoreszein angiographic findings. Ophthalmology 185: 168–178

    Article  CAS  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Universitätsaugenklinik Magdeburg, Leipziger Straße 44, 39120, Magdeburg, Deutschland

    T. Wecke, C. Knop, W. Schreiber & W. Behrens-Baumann

Authors
  1. T. Wecke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Knop
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W. Schreiber
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. W. Behrens-Baumann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. Wecke.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wecke, T., Knop, C., Schreiber, W. et al. Intraokulare Bevacizumab-Injektionen bei seltenen Indikationen – zwei Kasuistiken. Ophthalmologe 106, 435–442 (2009). https://doi.org/10.1007/s00347-008-1782-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00347-008-1782-3

Schlüsselwörter

Keywords

Search

Navigation